Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
141 questions in 31 reviews · Emergency and Critical Care
current versionsNo studies 141 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
HFNC vs NIPPV or NIV Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support High‐flow nasal cannulae for respiratory support in adult intensive care patients (2021) · Cochrane | no estimate extracted | NR | No studies |
Surfactants vs control Fitness to return to work at 12 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
N‐acetylcysteine vs control Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
N‐acetylcysteine vs control Duration of mechanical ventilation · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
N‐acetylcysteine vs control Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
N‐acetylcysteine vs control Adverse events Defined as leading to discontinuation of study medication · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
N‐acetylcysteine vs control Fitness to return to work at 12 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Statins vs control Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Statins vs control Adverse events Defined as leading to discontinuation of study medication · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Statins vs control Fitness to return to work at 12 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐agonist vs control Late all‐cause mortality (> 3 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐agonist vs control Duration of mechanical ventilation · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐agonist vs control Fitness to return to work at 12 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs control Adverse events Defined as leading to discontinuation of study medication; or for studies with standard care control, defined by study authors as "serious adverse events" · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs control Fitness to return to work at 12 months · adults with acute respiratory distress syndrome Pharmacological agents for adults with acute respiratory distress syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Buffered solutions vs 0.9% saline Electrolyte disturbances · critically ill adults and children Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children (2019) · Cochrane | no estimate extracted | NR | No studies |
Early enteral nutrition with supplemental parenteral nutrition (SPN) vs delayed enteral nutrition with SPN Hospital length of stay (measured in days) · critically ill adults Early enteral nutrition (within 48 hours) versus delayed enteral nutrition (after 48 hours) with or without… (2019) · Cochrane | no estimate extracted | NR | No studies |
Early enteral nutrition with supplemental parenteral nutrition (SPN) vs delayed enteral nutrition with SPN Pneumonia (as defined by the authors) ( · critically ill adults Early enteral nutrition (within 48 hours) versus delayed enteral nutrition (after 48 hours) with or without… (2019) · Cochrane | no estimate extracted | NR | No studies |
Early enteral nutrition with supplemental parenteral nutrition (SPN) vs delayed enteral nutrition with SPN Feed intolerance or gastrointestinal complications (as defined by the authors) · critically ill adults Early enteral nutrition (within 48 hours) versus delayed enteral nutrition (after 48 hours) with or without… (2019) · Cochrane | no estimate extracted | NR | No studies |
Mobilization of community first responders (CFRs) in addition to routine emergency medical services (EMS) care vs routine EMS care Neurological function at hospital discharge, measured by cerebral performance category (CPC) · adults and children more than 4 weeks old suffering from OHCA Community first responders for out‐of‐hospital cardiac arrest in adults and children (2019) · Cochrane | no estimate extracted | NR | No studies |
Mobilization of community first responders (CFRs) in addition to routine emergency medical services (EMS) care vs routine EMS care Neurological function at 30 days, measured by cerebral performance category (CPC) · adults and children more than 4 weeks old suffering from OHCA Community first responders for out‐of‐hospital cardiac arrest in adults and children (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison: outcome · participants at risk of high altitude illness Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison: outcome · participants at risk of high altitude illness Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparisons: outcome · participants at risk of high altitude illness Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes and intervention · people suffering from high altitude illness Interventions for treating acute high altitude illness (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · people suffering from high altitude illness Interventions for treating acute high altitude illness (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Complete relief of AMS symptoms · people suffering from high altitude illness Interventions for treating acute high altitude illness (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · people suffering from high altitude illness Interventions for treating acute high altitude illness (2018) · Cochrane | no estimate extracted | NR | No studies |
Haloperidol vs placebo Cognitive impairment · critically ill patients 18 years or older demanding mechanical ventilation within the first 72 hours (Page 2013) or… Interventions for preventing intensive care unit delirium in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Physical and cognitive therapy vs standard care The event rate of ICU delirium measured by the CAM‐ICU · critically ill patients 18 years or older treated for respiratory failure or septic or both, cardiogenic or… Interventions for preventing intensive care unit delirium in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
BIS monitoring vs clinical assessment Other important secondary outcomes like Any‐cause mortality, ventilator‐associated pneumonia, hospital LOS, amount of sedative agents used, long term functional outcomes and quality of life were not reported in any studies · Mechanically ventilated adults in the intensive care unit BIS monitoring versus clinical assessment for sedation in mechanically ventilated adults in the intensive… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs enteral and parenteral nutrition Number of ventilator‐free days up to day 28 · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs enteral and parenteral nutrition Adverse events: aspiration (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs enteral and parenteral nutrition Adverse events: sepsis (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs enteral and parenteral nutrition Adverse events: vomiting (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs parenteral nutrition Number of ICU‐free days up to day 28 · critically ill adults admitted to the ICU for trauma, emergency, or surgical care; population excluded people with… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Enteral vs enteral and parenteral nutrition Number of ICU‐free days up to day 28 · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes… Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for… (2018) · Cochrane | no estimate extracted | NR | No studies |
Automated monitoring systems vs standard care Time to initiation of fluid resuscitation (Time to initiation starts at the time of admission) · participants of any age admitted to the intensive care or critical care unit for any reason (including, but not… Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients (2018) · Cochrane | no estimate extracted | NR | No studies |
Automated monitoring systems vs standard care Quality of life measured at the latest available time point post‐discharge from ICU (preferred measure SF‐36 then EQ‐5D) · participants of any age admitted to the intensive care or critical care unit for any reason (including, but not… Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs no agent Quantity and quality of sleep as measured through reports of participants or family members or by personnel assessments Data collected at end of study · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs another agent specifically administered to promote sleep Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs no agent Anxiety or depression, or both, as measured using validated tools Data collected at end of study · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs no agent Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs propofol at a different rate or dose Quantity and quality of sleep as measured by PSG, actigraphy, BIS or EEG Data collected at end of study · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs propofol at a different rate or dose Anxiety or depression, or both, as measured using validated tools Data collected at end of study · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Propofol for the promotion of sleep in the intensive care unit vs propofol at a different rate or dose Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adults in the intensive care unit Propofol for the promotion of sleep in adults in the intensive care unit (2018) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone vs placebo Risk of adverse events ‐ not reported · participants at risk of high altitude illness Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs (2018) · Cochrane | no estimate extracted | NR | No studies |
Acetazolamide vs spironolactone Risk of adverse events ‐ not reported · participants at risk of high altitude illness Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs (2018) · Cochrane | no estimate extracted | NR | No studies |